The topic of statins has come up a few times. Here are two relevant items to read:

http://www.ncbi.nlm.nih.gov/pubmed/24613180

http://www.pharmacylearningnetwork.com/articles/what-effect-statins-hcv-infected-patients-liver-disease

Now looking to interactions:

Sofosbuvir Coadministration has not been studied. Simvastatin is an inhibitor of P-gp and may increase sofosbuvir concentrations. However, increasing sofosbuvir concentrations has been shown not to increase the predominant metabolite GS-331007, therefore no dose change should be required.

Ledipasvir Coadministration has not been studied but may increase simvastatin concentrations due to inhibition of P-gp and BCRP by ledipasvir. Use with caution. The dose of simvastatin should be titrated carefully and the lowest necessary dose should be used while monitoring for safety.

Daclatasvir Coadministration has not been studied but is expected to increase simvastatin concentrations due to inhibition of OATP1B1 and BRCP by daclatasvir. Use with caution. A dose reduction of simvastatin may be required, monitor lipid levels and CK and for increased side effects of simvastatin such as muscle pain.

So it looks like from the interactions point of view it is workable.

Now statins are not 100% safe. In fact they have a 10% side effect profile (that can require stopping them) where the side effects are muscle and liver enzyme elevation with muscle pain and feeling nauseous being the commonly reported patient feelings associated with this.

I just gave this advice to a patient whose Specialist wants to add in a statin to his Twinvir for GT1

How about 2 weeks to 1 month of straight DAAs to get your LFTs normal, and then drop in the statin?

Please recognise that embarking on statin use as a Ribavirin like booster is currently entirely experimental. YMMV.